Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 10/20 | 0.36 |
| ▸ | CDK8 | P49336 | 10/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 7/20 | 0.35 |
| ▸ | CDK19 | Q9BWU1 | 6/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.33 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20505709 | 1.00 | MAP2K1 (0.38) | MAP2K1CCNCCDK8MKNK1HASPIN | |
| SCHEMBL5474613 | 0.84 | DAO (0.45) | PDPK1 | |
| SCHEMBL35211498 | 0.79 | PKN1 (0.36) | MKNK1NR3C1NR3C2PKN1PKN2 | |
| SCHEMBL18322242 | 0.75 | KDM4E (0.49) | — | |
| SCHEMBL29882535 | 0.75 | GABRA1 (0.40) | NR3C1NR3C2 | |
| SCHEMBL14311952 | 0.74 | BACE1 (0.39) | MAP2K1CCNCCDK8MKNK1HASPIN | |
| SCHEMBL29519596 | 0.74 | BACE1 (0.39) | MAP2K1CCNCCDK8MKNK1HASPIN | |
| SCHEMBL20506664 | 0.73 | CCNC (0.38) | MAP2K1CCNCCDK8HASPINCDK19 | |
| SCHEMBL27825853 | 0.73 | ADORA3 (0.32) | — | |
| SCHEMBL1194081 | 0.72 | HRH4 (0.56) | MAP2K1CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522613-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| CN-119585248-A | Heteroaryl derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-114945571-A | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2022-08-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | MAP2K1 2956/4885CCNC 2004/4885CDK8 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.